Protection from Viral Infections by Human Milk Oligosaccharides: Direct Blockade and Indirect Modulation of Intestinal Ecology and Immune Reactions

Betsy Yang¹, Hau Chuang² and Rong-Fu Chen*³

¹Biology Class of 2014, University of North Carolina, Chapel Hill, NC 27599, USA
²Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan;
³Department of Medical Research, Show Chwan Memorial Hospital in Chang Bing, Lu-gang, Changhua 505, Taiwan

Abstract: Sugar-lectin interactions play an important role in viral infections. Many viruses, such as human immunodeficiency virus (HIV), Ebola, dengue, cytomegalovirus, and hepatitis C, possess glycans that recognize C-type lectins, especially CD209 (DC-SIGN), for infection. Other viruses possess lectins on their surfaces that recognize glycan epitopes on human epithelial cells for infection. Human and avian influenza viruses recognize different glycan epitopes, sialic acid-α2,6 galactose (SA-α2,6Gal) and SA-α2,3Gal, respectively, as their receptors, resulting in different host ranges for these two viruses. We and others have shown that sigalagalactosides and fucosyllactoses are receptors for enterovirus 71 and norovirus infections, respectively; human milk oligosaccharides (HMOs) could block enterovirus 71 and norovirus infections. Several lines of evidence also suggest that HMOs cannot only mimic viral receptors and block viral infections, but also raise immune responses through sugar/lectin (galactosides/galactins and sialylglycans/Siglecs) interactions and improve gut ecology by nurturing intestinal cells and/or intestinal microbiota. This review article summarizes how and why HMOs directly or indirectly protect humans from viral infections.

Keywords: Fucosyltransferase, Lactose, Galactose, Glycosyltransferase, Glycan, Human milk oligosaccharides (HMOs), Lectin, Lewis X, Sialic acid, Viral infection.

VIRAL INFECTIONS MEDIATED BY SUGAR-LECTIN INTERACTIONS

Microorganisms possess pathogen-associated molecular patterns (PAMPs) to recognize hosts during infection; human hosts have pattern recognition receptors (PRRs) to detect pathogens for immune responses and defense [1]. The interactions between PAMPs and PRRs include the sugar-lectin interactions that play an important role in the infection of human cells by viruses [2, 3]. Many viruses possess glycan epitopes on their surfaces that recognize receptors (lectins) on human cells. It is well known that human immunodeficiency virus (HIV) possesses glycans (high mannose type) on gp120 that bind dendritic-cell-specific ICAM-3–grabbing non-integrin (DC-SIGN, also called CD209) during infection of human leukocytes [3]. Viruses such as Ebola, dengue, cytomegalovirus, and hepatitis C also possess surface glycans that recognize DC-SIGN or other C-type lectins during infection [3-6] (Table 1). In contrast, other viruses possess surface lectins that recognize glycans on human epithelial cells. Human and avian influenza viruses recognize different glycan epitopes, sialic acid-α2,6 galactose (SA-α2,6Gal) and SA-α2,3Gal, respectively, as their receptors, resulting in different host ranges for these two viruses [7]. Coxsackievirus A24 recognizes SA-α2,3Gal on intestinal cells as a receptor [8]; we and others have shown that sialogalactosides and fucosyllactoses [9] and sialomucin (CD162) [10] are receptors for enterovirus 71 infection of intestinal cells. Both SA-α2,6Gal and SA-α2,3Gal from human milk oligosaccharides (HMOs) have been shown to block enterovirus 71 infection of DLD-1 intestinal cells [9]. Moreover, norovirus and rotavirus recognize blood group carbohydrates and sialylglycoproteins, respectively, as receptors. Human milk containing secretory blood group carbohydrates such as fucosylated Lewis antigens and sialylglycoproteins such as lactadherin have been shown to prevent infection by these viruses [11, 12]. Differential expression of cell surface glycans or lectins and exogenous intake of soluble oligosaccharides from human milk may block or prevent viral infections.

HMOS CONTAIN POLYLACTOSYL OLIGOSACCHARIDES CAPABLE OF NURTURING MICROBIOTA IN THE INFANT GUT

It is well known that infants who are breastfed have fewer respiratory and gastrointestinal infections than those who are fed cow’s milk infant formula [12, 13]. The composition and diversity of oligosaccharides in human milk, particularly in colostrum, are very different from those of cow’s milk [14-16]. The protective effects of human milk can be...
attributed to HMOs rather than secretory IgA because cow’s milk has IgA concentrations similar to that of human milk but 20-fold lower concentrations of oligosaccharides [14, 15].

HMOs are made of lactose (galactose + glucose), fucose, N-acetylgalacosamine and N-acetylneuramic acid (sialic acid). Mass spectrometric analysis indicates that HMOs are composed of 2 to 32 oligosaccharides, of which the number of galactose or fucose residues can be up to 15. There is great diversity in the structural isomers seen in HMOs, estimated to include many thousands of oligosaccharides [15]; at present, 115 HMOs have been characterized [16]. Most HMOs are indigestible in the human gastrointestinal tract. However, it is generally accepted that HMOs can be digested by certain bacteria in the gut and are beneficial to the selection of microbiota that promotes better gut ecology. HMOs promote the growth of normal flora such as Lactobacillus and Bifidobacterium species in the infant gut [14, 17]. LoCascio et al. [18] have recently reported that Bifidobacterium longum in the infant gut preferentially utilizes short-chain over complex HMOs and is associated with the expression of glycosidases capable of degrading oligosaccharides. These results suggest that the prebiotic effects of HMOs are structure-specific and may vary depending on individual differences in maternal lactation and microbiota of the infant gut [13–19].

**STRUCTURES OF HMOS**

HMOs containing the lacto-\(\text{N}\)-biose core unit (LNB; Gal\(\beta\)1-3GlcNAc) are called ‘type 1’ structures; those with a lactosamine (Gal\(\beta\)1-4GlcNAc) core unit are called ‘type 2’ structures as shown in Fig. (1). Oligosaccharides in human milk are predominantly type 1 structures [16, 20]. Both LNB and lactosamine core units are repeatedly elongated from a \(\beta\)1-3 or \(\beta\) 1-4 para linkage to the terminal lactose (Gal\(\beta\)1-4Gle) [20]. More complex oligosaccharides contain additional \(\beta\)1-6 linkages in branched forms and side chain fucosylation via a1-2/3/4 linkages and/or sialylation via a2-3/6 linkages. Thus, HMOs containing poly-lacto-N-biose or poly-acetyllactosamine with fucosylated and/or sialylated compounds can be composed of hundreds to thousands of oligosaccharides. These compounds, with or without branched adducts, are usually stable and indigestible by human intestinal cells.

HMOs may serve as natural barriers for the prevention of microbial adhesion to cells and infection. Some HMOs have been shown to modulate epithelial glycosyltransferase expression, possibly regulating the surface glycan profiles that affect the susceptibility of human cells to viral infection [21-23]. One study found that the sialic acid in human milk was mostly bound to free oligosaccharides, while most of the sialic acid in infant formulas derived from cow’s milk was bound to glycoproteins [24].

**HMOS ARE SECRETARY CARBOHYDRATES, CAPABLE OF INTERFERING WITH MICROBIAL ADHESION TO HOST CELLS**

HMOs are secreted into breast milk by mammary glands. Approximately 90% of the HMOs in human breast milk are found undigested in infants’ feces [17-23]. This suggests that HMOs play other roles beyond their prebiotic effects on microbiota ecology [21]. In fact, there is evidence that HMOs stimulate epithelial cells and afford protection from infections by raising innate immunity and/or nurturing gut ecology [21, 22]. HMOs contain heterogeneously soluble glycans that are present in high concentrations (up to 12 g/l) in human milk, particularly in colostrum. Milk from animals such as cows and goats also contains oligosaccharides but generally 10-fold lower in concentration and less diverse in composition [16]. Varying amounts and compositions of oligosaccharides are found in different mothers in different stages of breast feeding. Structures and quantities of HMOs vary between maternal genotypes, particularly with respect to the content of fucosylated oligosaccharides, which determines whether HMOs are secreted or not.
BLOOD GROUP CARBOHYDRATES IN HMOS PROTECT INFANTS FROM INFECTIONS

The blood group types A, B, O, and Lewis are determined by carbohydrate compositions. The H antigen is a tetraose carbohydrate consisting of galactose, N-acetylglucosamine, galactose, and fucose attached to a membrane protein or ceramide on human cells, including red blood cells. The blood group A antigen results from a glycosyltransferase that adds N-acetylgalactosamine to the galactose end of the H antigen. The blood group B antigen results from another glycosyltransferase that adds galactose to the galactose end of the H antigen. Blood group O arises from an exon 6 deletion that eliminates glycosyltransferase activity, resulting in the expression of H antigen only, with no A or B antigen expression [25]. Lewis antigens are made of trioses or tetroses determined by the activity of fucosyltransferases (FUT2, FUT3, and FUT4). FUT2 converts the Lewis a antigen (Le^a, Gal-GlcNAc-Fuc) to Lewis b antigen (Le^b, Fuc-Gal-GlcNAc-Fuc) by transferring fucose to the galactose end of Le^a antigen [25,26]. This is the same fucosyltransferase (FUT2) that converts membrane-bound blood group A, B, and H antigens into soluble forms by transferring a fucose residue to the galactose end of the H antigen, allowing humans to secrete blood group antigens into body fluids, including human milk. Most humans (80%) carry the FUT2 gene and are thus capable of secreting blood group antigens; these individuals are referred to as ‘secretors’ (SeSe/Sese); the remaining 20%, called ‘non-secretors’ (sese), lack FUT2 expression and thus do not secrete blood group antigens. HMOs from nonsecretors’ milk possess no α-2-fucosylgalactosides, but do contain other α-3-fucosyl...
Table 2. HMO Functions and Mechanisms of Protection from Infections

<table>
<thead>
<tr>
<th>Protective Mechanism</th>
<th>HMO Components</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-microbial effects:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Prebiotics</td>
<td>Lactose, poly-lactosamine poly-lacto-N-biose etc.</td>
<td>Prevent bacterial infections after viral infections</td>
<td>[14–23]</td>
</tr>
<tr>
<td>2. Receptor Competition</td>
<td>Secretor HMOs:</td>
<td>Compete with viral receptors to block viral infections</td>
<td>[29–32]</td>
</tr>
<tr>
<td></td>
<td>-- secretory A, B, H, and Lewis b (Le(^b)) antigens</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other fucosylated HMOs:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-- Le(^a), Le(^b), and sLe(^a), etc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other sialylated HMOs:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SA (\alpha 2,3) galactose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SA (\alpha 2,6) galactose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell interactions:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Immune Regulation</td>
<td>Fucosyl HMOs</td>
<td>Bind or compete selectins to induce anti-inflammation</td>
<td>[47–49]</td>
</tr>
<tr>
<td></td>
<td>Galactosyl or sialyl HMOs</td>
<td>Bind or compete galectins or Siglecs mediated immune responses</td>
<td>[50–52]</td>
</tr>
</tbody>
</table>

would be particularly beneficial to infants, who are more susceptible to infections.

FUNCTIONS AND MECHANISMS OF HMOS ON THE PROTECTION FROM VIRAL INFECTIONS

Protection of infant infections and mortality by human milk has been historically attributed to its nutritional suitability for infants, IgA antibody content, and its lactose-enriched prebiotic effects [13-19]. Many recent studies have found the benefits of human milk to go beyond what can be attributed to nutrient content or prebiotic effects. Table 2 summarizes the 4 major functions of HMOS; the first 2 functions are related to anti-microbial effects and the other 2 functions are related to immune modulation through host cell interactions.

1. HMOs Act as Prebiotics

Human milk is enriched in lactose, polyacetyl lactosamine and poly-lacto-N-biose, which are indigestible by humans but nurture Lactobacillus and Bifidobacillus species in the gut. These normal flora metabolize lactose and HMOs containing polylactosamine and poly-lacto-N-biose. The metabolites from lactose, poly-lactosamine, and poly-lacto-N-biose favor the growth of normal flora but inhibit other pathogens by causing acidic conditions, resulting in better microbiota ecology [13-19]. The better microbiota ecology may, therefore, protect from offensive bacterial infections after viral infections.

2. Soluble HMOS Compete with Pathogen Adhesion and Infection

Oligosaccharides are usually soluble but are not necessarily secreted. HMOS are soluble glycans secreted by mammary glands. The secretory pathways of HMOS are not...
completely understood, but are presumably similar to those of mucosal glands in the gastrointestinal, respiratory, and urogenital tracts. HMOs become secretory through the transfer of fucose to a galactose or glucosamine residue at the $\alpha2$ position by fucosyltransferase 2 (FUT2) as described above. Most oligosaccharides in human milk are $\alpha2$-fucosylated and relatively protective from viral infections [35], and those without FUT2 called non-secretors are usually more susceptible to the infection by viruses that recognize fucosyl oligosaccharides as receptors [36]. In addition to FUT2, other fucosyltransferases (FUT3, FUT5, and FUT6) and sialyltransferases (e.g. ST6Gal) can affect the glycan profiles of human cells, thereby influencing susceptibility to infections by viruses whose entry is mediated by sialyl or fucosyl oligosaccharides [37,38]. For instance, addition of fucose to the $\alpha3$ position by FUT3 converts type 2 core antigen (Gal $\beta1,4$ GlcNAc) to Lewis X antigen (Le$^a$; Gal $\beta1,4$ GlcNAc $\alpha1,3$ Fuc) and converts blood H2 antigen (Fuc $\alpha1,2$ Gal $\beta1,4$ GlcNAc) to Lewis Y antigen (Le$^b$; Fuc $\alpha1,2$ Gal $\beta1,4$ GlcNAc $\alpha1,3$ Fuc) [39]. Lewis X components in human milk are able to bind to DC-SIGN and thereby prevent the capture and subsequent transfer of HIV-1 to CD4+ T lymphocytes [40]. Le$^a$ and Le$^b$ can be siaIylated by sialyltransferases at position $\alpha2,3$ or $\alpha2,6$, producing siaIyl Le$^a$ and siaIyl Le$^b$. sLe$^a$ has been shown to be the common receptor recognized by H5, H6, H7, and H9 avian influenza viruses [41]; sLe$^a$ in milk may therefore be able to inhibit avian influenza virus infections.

3. HMOs May Nurture Intestinal Cell Differentiation

Sialyl oligosaccharides in human milk are more prominent in colostrum [27, 42], which may benefit premature babies by decreasing the incidence of inflammatory bowel diseases via its anti-inflammatory effects [43]. Furthermore, siaIyl HMOs are high in human milk but much lower in infant formulas. Experimental studies show that a diet rich in sialic acid increases the brain sialic acid levels in infant animals, enhances expression of two learning-related genes, and promotes learning and memory [44]. Since most of HMOs (>90%) are ingestible in gastrointestinal tract, the concentration of HMOs in blood or brain may be too low to directly affect brain development. Thus, siaIyl HMOs may directly nurture growth and development of the gastro-intestinal tract that indirectly influence immunity and the brain development of infants. In support of this concept, recent studies demonstrated that HMOs mediate growth signals in intestinal cells through mechanisms other than the epidermal growth factor pathway [45, 46]. Whether the HMOs modulation of intestinal cell differentiation is associated with susceptibility of viral infections remains to be determined.

4. HMOs Act as Ligands for Innate Immune Responses

Recent evidence has shown that HMOs mediate signal cascades in immune and other types of cells. Fucosylated and siaIylated oligosaccharides can bind to selectins (P-selectin and E-selectin) on platelets and endothelial cells. Selectins expressed on activated endothelial cells bind to fucosic-containing Lewis antigens such as sLe$^a$ on leukocytes, which leads to leukocyte rolling. The leukocytes subsequently transmigrate into subendothelial regions and extravasate [47]. HMOs resemble secretory Lewis antigens and may compete for selectin binding, resulting in anti-inflammatory effects [48, 49]. The backbone of HMOs is formed by poly-N-acetyllactosamines, which can bind galactoside-binding lectins (galectins). Galectins are a family of lectins that bind beta-galactosides. At least 12 different galectins have been identified with a variety of functions including regulation of cell growth, proliferation, and apoptosis, as well as immune functions [50]. Expression and interactions of galactosides and galectins may affect gut ecology and leukocyte function that may influence anti-viral defense. Different poly-lactosyl oligosaccharides in HMOs have varied affinities to different galectins, resulting in different immune regulation [51]. Many HMOs also contain siaIic acid ($\alpha2$-3 and/or $\alpha2$-6) bound to galactose or glucosamine. SiaIic acid-containing oligosaccharides have been shown to bind receptors called siaIic acid binding immunoglobulin-like lectins (Siglecs). There are at least 12 Siglecs that have been identified. Most of them have two conserved ITIM-like motifs (immunoreceptor tyrosine-based inhibitory motifs) in their cytoplasmic tails, suggesting their involvement in cellular activation or inactivation [52]. HMOs with siaIic acid side chains, which may recognize certain Siglecs on intestinal cells and leukocytes, have been proposed to mediate immunoregulatory functions [20, 21].

In summary, HMOs possess antiviral activity that is related to a direct blockade of viral infection or indirect modulation of intestinal ecology and immune responses. In addition to HMOs, glycoproteins in milk such as transferrin which has been shown to have potent activities against hepatitis B virus, human immunodeficiency virus and human cytomegalovirus replication [53,54]. Another mucin glycoprotein with molecular weight of 46-kD in human milk has also been shown to mediate antiviral activity directed against rotavirus [55]. Dietary supplements with HMOs or milk glycoproteins might be suitable for the prevention of infections in infants because of their stability and sweet taste [33, 34]. Further studies on the protective mechanisms of HMOs against viral infections by modulating cell surface expression of sugar epitopes or lectins, or by additional intake of exogenous HMOs might provide better strategies for prevention of viral infections.

REFERENCES


Lewis antigen system. Retrieved from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Lewis_antigen_system


Lewis antigen system. Retrieved from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Lewis_antigen_system


Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha1, 2Gal beta1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003; 278: 14112-20.